Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Novel Pharmacological Approaches to the Treatment of Depression
Elias Elias, Ariel Y. Zhang, Melissa T. Manners
Life (2022) Vol. 12, Iss. 2, pp. 196-196
Open Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

Neurotransmitter systems in the etiology of major neurological disorders: Emerging insights and therapeutic implications
Mallikarjuna Nimgampalle, Harshini Chakravarthy, Sapana Sharma, et al.
Ageing Research Reviews (2023) Vol. 89, pp. 101994-101994
Closed Access | Times Cited: 66
Peroxisome Proliferator-Activated Receptors and the Hallmarks of Cancer
Nicole Wagner, Kay‐Dietrich Wagner
Cells (2022) Vol. 11, Iss. 15, pp. 2432-2432
Open Access | Times Cited: 44
Is depression the missing link between inflammatory mediators and cancer?
Barbara Polityńska, Olga Pokorska, Anna M. Wojtukiewicz, et al.
Pharmacology & Therapeutics (2022) Vol. 240, pp. 108293-108293
Closed Access | Times Cited: 43
Thymoquinone-Enriched Naringenin-Loaded Nanostructured Lipid Carrier for Brain Delivery via Nasal Route: In Vitro Prospect and In Vivo Therapeutic Efficacy for the Treatment of Depression
Farheen Fatima Qizilbash, Muhammad Usama Ashhar, Ameeduzzafar Zafar, et al.
Pharmaceutics (2022) Vol. 14, Iss. 3, pp. 656-656
Open Access | Times Cited: 38
Glutamatergic neurotransmission: A potential pharmacotherapeutic target for the treatment of cognitive disorders
Pratik Chakraborty, Abhijit Dey, Abilash Valsala Gopalakrishnan, et al.
Ageing Research Reviews (2023) Vol. 85, pp. 101838-101838
Closed Access | Times Cited: 23
The role of microRNAs in depression
Ruidong Ding, Dingyuan Su, Qian Zhao, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 18
Flavonols in Action: Targeting Oxidative Stress and Neuroinflammation in Major Depressive Disorder
Maja Jazvinšćak Jembrek, Nada Oršolić, Dalibor Karlović, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 6888-6888
Open Access | Times Cited: 17
Cardamom oil ameliorates behavioral and neuropathological disorders in a rat model of depression induced by reserpine
Alaa A. Abdel-Rasoul, Nabil Saleh, Eman N. Hosny, et al.
Journal of Ethnopharmacology (2023) Vol. 308, pp. 116254-116254
Closed Access | Times Cited: 15
Peroxisome proliferator‐activated receptors as therapeutic target for cancer
Yuqing Wang, Feifei Lei, Yiyun Lin, et al.
Journal of Cellular and Molecular Medicine (2023) Vol. 28, Iss. 5
Open Access | Times Cited: 14
GluN2A and GluN2B N-Methyl-D-Aspartate Receptor (NMDARs) Subunits: Their Roles and Therapeutic Antagonists in Neurological Diseases
Amany Digal Ladagu, Funmilayo Eniola Olopade, Adeboye Adejare, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 11, pp. 1535-1535
Open Access | Times Cited: 14
Efficacy, Tolerability, and Safety of Toludesvenlafaxine for the Treatment of Major Depressive Disorder—A Narrative Review
Octavian Vasiliu
Pharmaceuticals (2023) Vol. 16, Iss. 3, pp. 411-411
Open Access | Times Cited: 13
Gypenoside XVII, an Active Ingredient from Gynostemma Pentaphyllum, Inhibits C3aR-Associated Synaptic Pruning in Stressed Mice
Man-Man Zhang, Guo-Ming Huo, Jie Cheng, et al.
Nutrients (2022) Vol. 14, Iss. 12, pp. 2418-2418
Open Access | Times Cited: 19
GALR2 and Y1R agonists intranasal infusion enhanced adult ventral hippocampal neurogenesis and antidepressant‐like effects involving BDNF actions
Jose Erik Alvarez‐Contino, Estela Díaz‐Sánchez, Marina Mirchandani‐Duque, et al.
Journal of Cellular Physiology (2023) Vol. 238, Iss. 2, pp. 459-474
Open Access | Times Cited: 12
The Role of Genetics in the Development and Pharmacotherapy of Depression and Its Impact on Drug Discovery
Agata Zięba, Dariusz Matosiuk, Agnieszka A. Kaczor
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2946-2946
Open Access | Times Cited: 12
Effect of a New Substance with Pyridoindole Structure on Adult Neurogenesis, Shape of Neurons, and Behavioral Outcomes in a Chronic Mild Stress Model in Rats
Alexandra Zvozilová, Alexandra Reichova, Mojmı́r Mach, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 845-845
Open Access | Times Cited: 3
Pyrazoline Derivatives as Promising MAO-A Targeting Antidepressants: An Update
Diksha Choudhary, Rajwinder Kaur, Thakur Gurjeet Singh, et al.
Current Topics in Medicinal Chemistry (2024) Vol. 24, Iss. 5, pp. 401-415
Closed Access | Times Cited: 3
Adaptogenic action of diosgenin againsts chronic unpredictable mild stress-induced neuroimmune dysfunction of HPA axis reverses psychiatric behavior in mice
Benneth Ben‐Azu, Emmanuel O. Chidebe, Pere-Ebi Yabrade Toloyai, et al.
Deleted Journal (2024) Vol. 5, Iss. 2, pp. 200148-200148
Open Access | Times Cited: 3
Epigenetic Aging in Major Depressive Disorder: Clocks, Mechanisms and Therapeutic Perspectives
Muqtada Shaikh, Gaurav Doshi
European Journal of Pharmacology (2024) Vol. 978, pp. 176757-176757
Closed Access | Times Cited: 3
Research advances in huntingtin-associated protein 1 and its application prospects in diseases
Yongjiang Wu, Yanfei Wang, Yunchi Lu, et al.
Frontiers in Neuroscience (2024) Vol. 18
Open Access | Times Cited: 3
The Effects of Prenatal Dexamethasone Exposure on Brain Metabolic Homeostasis in Adulthood: Implications for Depression
Katarzyna Głombik, Magdalena Kukla-Bartoszek, Katarzyna Curzytek, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1156-1156
Open Access | Times Cited: 7
Decreased medial prefrontal cortex activity related to impaired novel object preference task performance following GALR2 and Y1R agonists intranasal infusion
Estela Díaz‐Sánchez, Alexander López‐Salas, Marina Mirchandani‐Duque, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 161, pp. 114433-114433
Open Access | Times Cited: 7
Indanone: a promising scaffold for new drug discovery against neurodegenerative disorders
Ranju Bansal, Ranjit Singh, Tuhin Dutta, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 8, pp. 104063-104063
Closed Access | Times Cited: 2
Targeting the Arginine Vasopressin V1b Receptor System and Stress Response in Depression and Other Neuropsychiatric Disorders
Stephen Kanes, Lara Dennie, Philip Perera
Neuropsychiatric Disease and Treatment (2023) Vol. Volume 19, pp. 811-828
Open Access | Times Cited: 6
Effect of Chronic Serotonin-2 Receptor Agonist or Antagonist Administration on Serotonin-1A Receptor Sensitivity
Johannes Hensler
Neuropsychopharmacology (1998) Vol. 19, Iss. 5, pp. 354-364
Open Access | Times Cited: 39
Precision Medicine in Depression: The Role of Proteomics and Metabolomics in Personalized Treatment Approaches
Mohamad Jaber, Hamza Kahwaji, S Nasr, et al.
Advances in experimental medicine and biology (2024), pp. 359-378
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top